It emphasizes the salient phenotypic features of marrow myeloma cells, in contrast with normal plasma cells. The myeloma cell phenotype is discussed from the perspective of both tissue section immunohistochemistry (IHC) and flow cytometry (FACS analysis). The specific criteria for myeloma diagnosis are...
The blood B- cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr Top Microbiol Immunol 1995; 194:17 - 24.Bergsagel PL, Masellis-Smith A, Belch AR, et al. The blood B-cells and bone marrow plasma cells in patients with multiple ...
Multiple Myeloma-Bone Marrow Plasma is obtained by centrifuging the Multiple Myeloma-bone marrow. The plasma has a diminished number of cells and platelets. Multiple Myeloma-Bone Marrow plasma is available in both the newly diagnosed and relapsed/refractory stages. For research use only 资料下载 相...
Bone marrow is thought to be a primary hematopoietic organ. However, accumulated evidences demonstrate that active function and trafficking of immune cells, including regulatory T cells, conventional T cells, B cells, dendritic cells, natural killer T (N
We have verified the hypothesis that multiple myeloma (MM) may be disseminated by circulating clonogenic cells that selectively home to the bone marrow (BM) to receive the signal(s) leading to proliferation, terminal differentiation, and production of the osteoclast activating factors. Long-term cult...
This is the general mechanism how genetic transformation of plasma cells leads to development of multiple myeloma in mostly elderly individuals. The abnormal plasma cells overflow from the bone marrow of origin and via blood are transported to bone marrow in other parts of the body. Thus, bone ...
Multiple myeloma (MM) is a hematological malignancy, characterized by expansion of monoclonal plasma cells in the bone marrow (BM) [1]. Bortezomib (BZ) was the first proteasome inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of MM and is currently one of th...
red blood cell receptor-bearing cells from the bone marrow of patients suppressed responses of the patients' PBL's to autologous -treated bone marrow plasma cells and to allogeneic stimuli in one-way mixed leukocyte culture. Complement receptor-bearing cells suppressed the response to pokeweed . ...
AL amyloidosisbone marrow plasma cellsprognostic impactmultiple myelomaWe studied seventy-five patients with relapsed MM treated with bortezomib-based regimens. DNA was isolated from bone marrow samples at the time of relapse. Global methylation was determined by ELISA, and CpG island DNA methylation ...
Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.doi:10.1038/leu.2013.27Multiple myeloma (MM) is a deadly hematopoietic malignancy characterized by proliferation of malignant plasma cells in the bone marrow (BM) and bone ...